Downregulation of MHC–I components is a potential oncogenic driver [29,30,31,32,33], and the targeting of epigenetic ‘readers’, ‘writers’ and ‘erasers’ might facilitate re–expression of cell surface MHC complexes to reengage host immune pathways in cancer cells. Here, HLA-C is linked to cancer.